379 results on '"Siris, E."'
Search Results
2. Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment
3. Correction to: The clinician’s guide to prevention and treatment of osteoporosis
4. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design
5. Hip fracture trends in the United States, 2002 to 2015
6. Is the association between hip fractures and seasonality modified by influenza vaccination? An ecological study
7. Self-perception of fracture risk: what can it tell us?
8. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA
9. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
10. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
11. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group
12. Correction to: Hip fracture trends in the United States, 2002 to 2015
13. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study
14. Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW)
15. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW)
16. What’s in a name? What constitutes the clinical diagnosis of osteoporosis?
17. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women
18. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial
19. Rib fracture as a predictor of future fractures in young and older postmenopausal women: National Osteoporosis Risk Assessment (NORA)
20. Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures
21. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
22. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)
23. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)
24. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data
25. Osteoporosis care at risk in the United States
26. Effects of risedronate on fracture risk in postmenopausal women with osteopenia
27. Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study
28. Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)
29. Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study
30. An approach for identifying postmenopausal women age 50–64 years at increased short-term risk for osteoporotic fracture
31. Enhanced prediction of fracture risk combining vertebral fracture status and BMD
32. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA)
33. Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study
34. Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
35. Paget's Disease of Bone
36. Antiresorptive Effect of a Single Infusion of Microgram Quantities of Zoledronate in Paget's Disease of Bone
37. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application
38. Abstracts from the symposium on recent advances in Paget’s disease of bone and related bone diseases
39. Beyond bone mineral density: can existing clinical risk assessment instruments identify women at increased risk of osteoporosis?
40. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study
41. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
42. Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study
43. Failure to Perceive Increased Risk of Fracture in Women >= 55 Years. The Global Longitudinal Registry of Osteoporosis in Women
44. DISEASE-SPECIFIC PERCEPTION OF FRACTURE RISK AND INCIDENT FRACTURE RATES AMONG POSTMENOPAUSAL WOMEN: THE GLOW REGISTRY
45. FRACTURE INCIDENCE IN OBESE POSTMENOPAUSAL WOMEN: THE GLOBAL STUDY OF OSTEOPOROSIS IN WOMEN (GLOW)
46. FAILURE TO PERCEIVE INCREASED RISK OF FRACTURE IN WOMEN 55 YEARS AND OLDER. THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN
47. Hip fracture trends in the United States, 2002 to 2015
48. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA
49. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women
50. Freedon Trial: Denosumab is not associated with fracture healing complication in postmenopausal women with osteoporosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.